Current issue #21, 2017

VED pricing methodology proposed by MoH fixes prices

Judging by the Russian Government draft resolution “On state registration and reregistration of maximum selling prices for VED-listed products”, the Russian Ministry of Health is about to plot a pricing revolution. The reform’s overall objective is to shift from the cost plus pricing to an indicative method, which is not only to result in fair drug prices but also place all market players on an equal footing. The current pricing methodology is thought to prejudice Russian manufacturers’ rights in price reregistration. However, good intentions may result in ill deeds, which is often the case in this country.

[PharmVestnik # 21, 27/06/2017, p. 1, cont’d p. 4]

MoH revises drug list forming rules

The Russian Government adopted amendments to the resolution No. 819 on approval of drug list forming rules. These are minimal so far. The most significant amendment is a direct relationship between the list of high-cost drugs procured under the Seven Diseases program and the targeted federal budget allocations. However, deeper changes will concern the new drug evaluation criteria, such as efficacy, health economic studies, etc. These amendments will be made later.

[PharmVestnik # 21, 27/06/2017, p. 2]

Full-scale contract manufacturing may start in Russia on January 1, 2018

Contract manufacturing does exist in Russia, but it has been limited so far. According to the State Institute of Medicinal Product...